Pharmacopeia

CWP-0021

Andexanet alfa

Haematology · Level 3

Core pharmacology

Class Group

Modified recombinant factor Xa decoy protein; direct factor Xa inhibitor reversal agent.

Main Action

Rapidly reduces anticoagulant activity of direct factor Xa inhibitors by binding/sequestering them.

Mechanism of action

Modified recombinant human factor Xa retains affinity for factor Xa inhibitors but lacks normal factor Xa catalytic procoagulant function. It also interacts with tissue-factor-pathway inhibitor.

Indications Uses

Historically provisionally authorised in Australia for reversal of apixaban/rivaroxaban in adults with life-threatening or uncontrolled bleeding; NOT currently ARTG-registered. Retained here for pharmacology/exam study.

Adverse Effects Toxicity

Thrombotic and ischaemic events, including stroke and myocardial infarction, are major safety concerns; infusion-related and other adverse reactions may occur. Clinical outcome benefit is uncertain.

Special Points

AUSTRALIA: provisional registration of ANDEXXA lapsed 20 May 2026; the product was removed from the ARTG. The NSW Medicines Formulary does not list andexanet alfa. Do not present this as routinely available for Australian ICU use; seek current local haematology/transfusion guidance for management of factor Xa inhibitor-related bleeding.

Source references

These October 2026 additions were reconciled against the linked sources. Refer to current local formulary guidance for clinical prescribing.